Opendata, web and dolomites

INTACt

ImmuNogenomics TArgeting Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 INTACt project word cloud

Explore the words cloud of the INTACt project. It provides you a very rough idea of what is the project "INTACt" about.

incidence    immunotherapy    lack    neo    resistant    strategies    efficacy    investments    fresh    xenografts    manner    mortality    pressured    breakthroughs    cancer    serves    promise    tumor    time    vaccines    holds    highlighted    emphasizes    skin    economic    expended    enormous    unnecessary    recognition    types    costly    antigens    genetic    designed    therapy    caused    drug    treatment    toxicities    industry    mutations    candidates    burden    poc    lower    lethal    mediated    cells    biased    melanoma    commercializing    limitation    systematic    signature    innovative    plasma    immunological    reactive    therapies    distinctive    psychological    consuming    worldwide    landscape    combined    tool    designing    models    ultimate    unlike    genome    tumors    eliminated    therapeutic    person    business    arise    intact    lines    cell    significantly    immune    aggressive    patient    consequence    creation    antigen    returned    personalized    chemotherapy    patients    pharmaceutical    rna    ones    realizing    throughput    showing    composition   

Project "INTACt" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

Melanoma is the most aggressive, treatment-resistant and lethal type of skin cancer. Its increasing incidence worldwide emphasizes the need for new treatment strategies. Major recent breakthroughs in melanoma therapy have highlighted the role of immune T cell-mediated responses against tumor cells, showing that immune-system recognition of neo-antigens on cancer cells serves as a distinctive immunological signature. However, current strategies to identify neo-antigens are biased, costly and time-consuming. Directly addressing this major therapeutic limitation, this PoC project is aimed at commercializing an innovative tool, called INTACt, for designing highly personalized therapies for melanoma patients, ones that efficiently target the composition of patient-specific neo-antigens that arise as a consequence of mutations in a patient’s melanoma genome. INTACt is designed to identify neo-antigens in a high-throughput, systematic and cost-effective manner in cell lines, fresh tumors, patient-derived xenografts and plasma. INTACt will further identify the patient neo-antigen-reactive T cells to then be returned to the patient, using neo-antigen-specific T cells or RNA vaccines. Such personalized targeting of the patient’s melanoma genetic landscape is key to a significantly improved mortality. Unlike existing therapeutic strategies, INTACt may be considered the ultimate personalized immune therapy for the treatment of melanoma patients to be expended to other cancer types. This patient-specific tool will significantly lower patients’ economic and psychological burden caused by unnecessary chemotherapy and targeted therapy. INTACt also holds the promise of realizing value from enormous past investments in drug candidates that were eliminated due to person-specific toxicities or lack of efficacy as these can be combined with the neo-antigen-based immunotherapy. INTACt will thus enable the creation of new business models for the highly pressured pharmaceutical industry.

 Publications

year authors and title journal last update
List of publications.
2018 Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels
CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25805
Oncotarget 9/58 2019-06-05
2018 Michal Alon, Rafi Emmanuel, Nouar Qutob, Anna Bakhman, Victoria Peshti, Alexandra Brodezki, David Bassan, Mickey Kosloff, Yardena Samuels
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma
published pages: 641-648, ISSN: 1755-1471, DOI: 10.1111/pcmr.12705
Pigment Cell & Melanoma Research 31/5 2019-06-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

SmartForests (2020)

Smart Forests: Transforming Environments into Social-Political Technologies

Read More